Literature DB >> 16394779

Update of early respiratory failure in the lung transplant recipient.

John Granton1.   

Abstract

PURPOSE OF REVIEW: Respiratory failure remains the most common complication in the perioperative period after lung transplantation. Consequently it is important to develop an approach to diagnosis and the treatment of respiratory failure in this population. This review highlights the advances made in the understanding and treatment of lung transplant patients in the early postoperative phase. Owing to its relative importance, advances in the understanding and treatment of ischaemia-reperfusion injury are highlighted. RECENT
FINDINGS: The causes of respiratory failure and the complications seen after transplantation are time dependent, with ischaemia-reperfusion, infection, technical problems and acute rejection being the most common in the early perioperative phase, and obliterative bronchiolitis, rejection, and infections secondary to bacteria, fungi, and viruses becoming more prevalent after 3 months. The advances in lung preservation and postoperative care may be overshadowed by an increase in the complexity of the recipients and the use of more marginal organs. An improved mechanistic understanding of ischaemia-reperfusion injury has translated into potential therapeutic targets. The development of prospective clinical trials, however, is hampered by a relatively small sample of patients and a significant degree of heterogeneity in the lung transplant population.
SUMMARY: Many advances have been made in the understanding of ischaemia-reperfusion injury. Owing to the acute and long-term implications of this complication, interventions that reduce the risk of developing ischaemia-reperfusion need to be evaluated in prospective clinical trials.

Entities:  

Mesh:

Year:  2006        PMID: 16394779     DOI: 10.1097/01.ccx.0000198995.44943.63

Source DB:  PubMed          Journal:  Curr Opin Crit Care        ISSN: 1070-5295            Impact factor:   3.687


  14 in total

1.  Adenosine signaling via the adenosine 2B receptor is involved in bronchiolitis obliterans development.

Authors:  Yunge Zhao; Damien J LaPar; John Steidle; Abbas Emaminia; Irving L Kron; Gorav Ailawadi; Joel Linden; Christine L Lau
Journal:  J Heart Lung Transplant       Date:  2010-12       Impact factor: 10.247

2.  Rapamycin prevents bronchiolitis obliterans through increasing infiltration of regulatory B cells in a murine tracheal transplantation model.

Authors:  Yunge Zhao; Jacob R Gillen; Akshaya K Meher; Jordan A Burns; Irving L Kron; Christine L Lau
Journal:  J Thorac Cardiovasc Surg       Date:  2015-09-07       Impact factor: 5.209

3.  Prevention of the second stage of epithelial loss is a potential novel treatment for bronchiolitis obliterans.

Authors:  Yunge Zhao; John F Steidle; Gilbert R Upchurch; Irving L Kron; Christine L Lau
Journal:  J Thorac Cardiovasc Surg       Date:  2012-08-28       Impact factor: 5.209

4.  Natural killer T cell-derived IL-17 mediates lung ischemia-reperfusion injury.

Authors:  Ashish K Sharma; Damien J LaPar; Yunge Zhao; Li Li; Christine L Lau; Irving L Kron; Yoichiro Iwakura; Mark D Okusa; Victor E Laubach
Journal:  Am J Respir Crit Care Med       Date:  2011-02-11       Impact factor: 21.405

5.  Sphingosine-1-phosphate receptor 1 agonism attenuates lung ischemia-reperfusion injury.

Authors:  Matthew L Stone; Ashish K Sharma; Yunge Zhao; Eric J Charles; Mary E Huerter; William F Johnston; Irving L Kron; Kevin R Lynch; Victor E Laubach
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2015-04-24       Impact factor: 5.464

6.  NADPH oxidase in bone marrow-derived cells mediates pulmonary ischemia-reperfusion injury.

Authors:  Zequan Yang; Ashish K Sharma; Melissa Marshall; Irving L Kron; Victor E Laubach
Journal:  Am J Respir Cell Mol Biol       Date:  2008-09-11       Impact factor: 6.914

Review 7.  Pulmonary inflammation after lung transplantation.

Authors:  Victor E Laubach; Irving L Kron
Journal:  Surgery       Date:  2009-05-08       Impact factor: 3.982

8.  CD3+CD4-CD8- Double-negative αβ T cells attenuate lung ischemia-reperfusion injury.

Authors:  Joshua Hsu; Aravind Krishnan; Sul A Lee; Jefferey M Dodd-O; Bo S Kim; Peter Illei; Kristine Yarnoff; Abdel A Hamad; Hamid Rabb; Errol L Bush
Journal:  J Thorac Cardiovasc Surg       Date:  2019-11-02       Impact factor: 5.209

9.  CD4+ T lymphocytes mediate acute pulmonary ischemia-reperfusion injury.

Authors:  Zequan Yang; Ashish K Sharma; Joel Linden; Irving L Kron; Victor E Laubach
Journal:  J Thorac Cardiovasc Surg       Date:  2009-03       Impact factor: 5.209

10.  NADPH oxidase mediates synergistic effects of IL-17 and TNF-α on CXCL1 expression by epithelial cells after lung ischemia-reperfusion.

Authors:  Ashish K Sharma; Daniel P Mulloy; Lamvy T Le; Victor E Laubach
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2013-11-01       Impact factor: 5.464

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.